A previous study has indicated that GATA2 mutation is associated with a greater risk of cumulative incidence of relapse (CIR) or shorter leukemia-free survival (LFS) in newly diagnosed AML patients treated with a combination of decitabine, cytarabine, aclarubicin, and G-CSF (DCAG) [32]. Here, GATA2 is linked to acute myeloid leukemia.